SM
CLGN icon

Sabby Management’s CollPlant Biotechnologies CLGN Stock Holding History

Sabby Management’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,045
Closed -$229K – 170
2021
Q1 		$229K Buy
+17,045
New +$257K 0.04% 132

Other funds holding CLGN

RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
IMOV
Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
FA
Friess Associates Greenville, Delaware $59.9M AUM 3.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
WC
Weil Company San Diego, California $445M AUM 14.95% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's CLGN Position: Q2 2021 in Review

Sabby Management sold out of CollPlant Biotechnologies (CLGN) in Q2 2021, closing a stake of 17,045 shares — an estimated $229K sold.

Sabby Management first reported a position in CLGN in Q1 2021 and held it in 1 quarter. The position peaked at $229K in Q1 2021. 16 funds tracked by Wall St. Rank hold CLGN as of Q2 2021.

  • Sabby Management reported no remaining CollPlant Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Sabby Management sold 17,045 CollPlant Biotechnologies shares in Q2 2021, an estimated $229K.
  • Sabby Management first reported a position in CollPlant Biotechnologies in Q1 2021 and held it in 1 quarter.
  • Sabby Management's CollPlant Biotechnologies position peaked at $229K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2021.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.